Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 0.17x is 78% below its estimated 1-year average of 0.77x, near the low end of its estimated 1-year range (0.06x–1.39x).
As of 2026-10-06T12:00:54.203Z.
Calculation as of: 2026-10-06T12:00:54.203Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e7d16b5ba5167ceff619aa020f317ca223699ac3cb4068fa61dc11e0d5c4076
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
0.17x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.16x
median of 258 covered companies
CURRENT VS SECTOR MEDIAN
-95.91%
vs the sector median at left
Market Cap
$4.41M
EV/Sales Ratio
N/A
TTM Avg
2126.93x
3Y Avg
1896.72x
5Y Avg
1896.72x
Market Cap
$4.42M
EV/Sales Ratio
12.99x
TTM Avg
5.50x
3Y Avg
15.32x
5Y Avg
34.36x
Market Cap
$3.94M
EV/Sales Ratio
N/A
TTM Avg
0.35x
3Y Avg
5.55x
5Y Avg
4.43x
Market Cap
$4.79M
EV/Sales Ratio
0.54x
TTM Avg
5.83x
3Y Avg
31.22x
5Y Avg
31.22x
Market Cap
$4.96M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.32M | 0.17x | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | N/A | 2126.93x | 1896.72x | 1896.72x |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | 12.99x | 5.50x | 15.32x | 34.36x |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | N/A | 0.35x | 5.55x | 4.43x |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | 0.54x | 5.83x | 31.22x | 31.22x |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.48M | N/A | 1.52x | 2.03x | 233.77x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-02 | 0.06x |
| 2026-10-01 | 0.21x |
| 2026-09-30 | 0.36x |
| 2026-09-29 | 0.22x |
| 2026-09-28 | 0.22x |
| 2026-09-25 | 0.35x |
| 2026-09-24 | 0.29x |
| 2026-09-23 | 0.31x |
| 2026-09-22 | 0.54x |
| 2026-09-21 | 0.54x |
| 2026-09-18 | 0.51x |
| 2026-09-17 | 0.55x |
| 2026-09-16 | 0.60x |
| 2026-09-15 | 0.57x |
| 2026-09-14 | 0.81x |
| 2026-09-11 | 1.01x |
| 2026-09-10 | 0.91x |
| 2026-09-09 | 1.04x |
| 2026-09-08 | 1.11x |
| 2026-09-04 | 1.18x |
| 2026-09-03 | 1.29x |
| 2026-09-02 | 1.39x |
| 2026-09-01 | 1.31x |
| 2026-08-31 | 1.31x |
| 2026-08-28 | 1.35x |
| 2026-08-27 | 1.33x |
| 2026-08-26 | 1.03x |
| 2026-08-25 | 0.85x |
| 2026-08-24 | 0.79x |
| 2026-08-21 | 0.98x |
| 2026-08-20 | 0.77x |
| 2026-08-19 | 0.74x |
| 2026-08-18 | 0.78x |
| 2026-08-17 | 0.96x |
